255
Views
19
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Clinical and laboratory characterization of a large cohort of patients with Castleman disease retrospectively collected from a single center

, , , , , & show all
Pages 1308-1317 | Received 27 Feb 2009, Accepted 20 May 2009, Published online: 13 Aug 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Nikhil Munshi, Maneesha Mehra, Helgi van de Velde, Avinash Desai, Ravi Potluri & Jessica Vermeulen. (2015) Use of a claims database to characterize and estimate the incidence rate for Castleman disease. Leukemia & Lymphoma 56:5, pages 1252-1260.
Read now
Dong-yeop Shin, Yoon Kyung Jeon, Yong-sang Hong, Tae Min Kim, Se-hoon Lee, Dong-wan Kim, Inho Kim, Sung-soo Yoon, Dae Seog Heo, Seonyang Park & Byoung Kook Kim. (2011) Clinical dissection of multicentric Castleman disease. Leukemia & Lymphoma 52:8, pages 1517-1522.
Read now

Articles from other publishers (17)

Wenhui Chen, Ling Zhao, Lijuan Guo, Li Zhao, Hongtao Niu, Huifang Lian, Huaping Dai, Jingyu Chen & Chen Wang. (2022) Clinical and pathological features of bronchiolitis obliterans requiring lung transplantation in paraneoplastic pemphigus associated with Castleman disease. The Clinical Respiratory Journal 16:3, pages 173-181.
Crossref
Midori Filiz NishimuraYoshito NishimuraAsami Nishikori, Tadashi YoshinoYasuharu Sato. (2022) Historical and pathological overview of Castleman disease. Journal of Clinical and Experimental Hematopathology 62:2, pages 60-72.
Crossref
Midori Filiz Nishimura, Yoshito Nishimura, Asami Nishikori, Yukina Maekawa, Kanna Maehama, Tadashi Yoshino & Yasuharu Sato. (2021) Clinical and Pathological Characteristics of Hyaline-Vascular Type Unicentric Castleman Disease: A 20-Year Retrospective Analysis. Diagnostics 11:11, pages 2008.
Crossref
Leyi Wang, Lin Nong, Furong Li, Xue Wang, Rui Wang, Xixue Chen, Ping Tu, Yujun Dong, Ting Li, Xuejun Zhu & Mingyue Wang. (2020) Predominant Stroma-Rich Feature in Hyaline Vascular Variant of Castleman Disease Is Associated With Paraneoplastic Pemphigus. American Journal of Clinical Pathology 154:3, pages 403-413.
Crossref
Celina Wakisaka Maruta, Denise Miyamoto, Valeria Aoki, Ricardo Gomes Ribeiro de Carvalho, Breno Medeiros Cunha & Claudia Giuli Santi. (2019) Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview. Anais Brasileiros de Dermatologia 94:4, pages 388-398.
Crossref
Shu-Ping Han, Lin-Shien Fu & Lu-Jen Chen. (2019) Masked pemphigus among pediatric patients with Castleman’s disease. International Journal of Rheumatic Diseases 22:1, pages 121-131.
Crossref
Yujun Dong, Lu Zhang, Lin Nong, Lihong Wang, Zeyin Liang, Daobin Zhou, David C. Fajgenbaum, Hanyun Ren & Jian Li. (2018) Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease. Annals of Hematology 97:9, pages 1641-1647.
Crossref
Michael Haap, Julia Wiefels, Marius Horger, Annika Hoyer & Karsten Müssig. (2018) Clinical, laboratory and imaging findings in Castleman's disease – The subtype decides. Blood Reviews 32:3, pages 225-234.
Crossref
Muhammad Bilal Abid, Rachel Peck, Muhammad Abbas Abid, Wesam Al-Sakkaf, Yuening Zhang, Giles S. Dunnill, Konrad Staines, Iara-Maria Sequeiros & Lisa Lowry. (2018) Is tocilizumab a potential therapeutic option for refractory unicentric Castleman disease?. Hematological Oncology 36:1, pages 320-323.
Crossref
Yujun Dong, Mingyue Wang, Lin Nong, Lihong Wang, Xinan Cen, Wei Liu, Sainan Zhu, Yuhua Sun, Zeyin Liang, Yuan Li, Jinping Ou, Zhixiang Qiu & Hanyun Ren. (2015) Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor. British Journal of Haematology 169:6, pages 834-842.
Crossref
F Loreni, M Mancino & S Biffo. (2013) Translation factors and ribosomal proteins control tumor onset and progression: how?. Oncogene 33:17, pages 2145-2156.
Crossref
Seyoung SeoChanghoon YooDok Hyun YoonShin KimJung Sun ParkChan-Sik ParkJooryung HuhCheolwon Suh. (2014) Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience. Blood Research 49:4, pages 253.
Crossref
R. Borie, M. Riquet, C. Danel, B. Crestani & P. Mordant. (2013) Maladie de Castleman médiastinale : mise au point. Revue de Pneumologie Clinique 69:6, pages 354-357.
Crossref
Damin Xu, Jicheng Lv, Yujun Dong, Suxia Wang, Tao Su, Fude Zhou, Wanzhong Zou, Minghui Zhao & Hong Zhang. (2012) Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrology Dialysis Transplantation 27:suppl_3, pages iii119-iii125.
Crossref
Theresa W. Muskardin, Bruce A. Peterson & Jerry A. Molitor. (2012) Castleman disease and associated autoimmune disease. Current Opinion in Rheumatology 24:1, pages 76-83.
Crossref
Jason J Everly, R Carlin Walsh, Rita R Alloway & E Steve Woodle. (2009) Proteasome inhibition for antibody-mediated rejection. Current Opinion in Organ Transplantation 14:6, pages 662-666.
Crossref
J J Shah & R Z Orlowski. (2009) Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23:11, pages 1964-1979.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.